Physician profile
Sara Davidovich
NPI 1467089631
$5,392.18
in general payments reported to CMS, 2019-2025
26 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 89% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,697 · 2024: $1,916 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,499 · Travel and Lodging: $512 · Long Term Medical Supply Or Device Loan: $307 · Education: $62.50 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,498.72 |
| Travel and Lodging | $512.07 |
| Long Term Medical Supply Or Device Loan | $307.00 |
| Education | $62.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,031.23 | 2023-2025 | |
| Integra Lifesciences Corporation | $663.03 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Amgen INC. | $515.60 | 2024-2025 | Krystexxa |
| Kerecis Limited | $396.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Solventum Corporation | $247.66 | 2024-2025 | V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice, Prevena |
| Horizon Therapeutics Plc | $241.05 | 2023 | Krystexxa |
| Medline Industries Lp | $179.62 | 2023-2024 | |
| Bioventus LLC | $178.09 | 2025 | Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $177.03 | 2025 | Physio-Stim |
| Medtronic, INC. | $176.81 | 2023 | Endurant Iis |
| Smith+Nephew, INC. | $172.91 | 2023-2024 | Grafix Pl, Stravix, Stravix Pl |
| Musculoskeletal Transplant Foundation INC. | $165.92 | 2023 | |
| Paratek Pharmaceuticals, INC. | $165.05 | 2023-2025 | Nuzyra |
| Lifenet Health | $143.73 | 2025 | Theragenesis Wound Matrix |
| Stryker Corporation | $137.71 | 2024 | Alphavent, Iconix, N/A |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $136.30 | 2024 | |
| Averitas Pharma INC. | $130.65 | 2023 | Qutenza |
| Organogenesis INC. | $121.97 | 2024 | |
| Sanara Medtech INC. | $119.04 | 2025 | Celleraterx |
| Biopoly LLC | $105.00 | 2024 | |
| Medical Device Business Services, INC. | $72.28 | 2024 | Vistaseal |
| Paragon 28, INC. | $31.42 | 2024 | Mtp |
| Biocomposites INC | $29.40 | 2025 | Stimulan |
| Abbvie INC. | $20.08 | 2024 | |
| Novo Nordisk INC | $18.22 | 2024 | Wegovy |
| Advanced Oxygen Therapy INC. | $15.88 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Davidovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.